Network News
Cardiologist Dr. Kai-Uwe Jarr is researching why the body’s own immune system does not recognize and remove the deposits in blood vessels that can lead to life-threatening circulatory disorders. For his research into immunotherapy for atherosclerosis and the establishment of his own junior research group at the Heidelberg Medical Faculty of Heidelberg University, he will […]
read more
Heidelberg student team: overall victory in the renowned iGEM competition in the field of synthetic biology
The Ruperto Carola team impressed with an innovative method for the targeted modification of the 3D structure of genetic material in human cells A team of students from Heidelberg University took part in the prestigious International Genetically Engineered Machine Competition (iGEM) for synthetic biology with great success – overall victory. It took first place in […]
read more
Rheumatism and cancer: Heidelberg rheumatologist receives three awards
Dr. Karolina Gente is researching at Heidelberg University’s Faculty of Medicine how cancer can be detected earlier in rheumatism patients and how inflammatory rheumatic diseases can be treated safely in cancer patients. She has set up a consultation hour at Heidelberg University Hospital where she advises patients on these issues, soon also via telemedicine. Her […]
read more
Universität Heidelberg with 15 “Highly Cited Researchers
International evaluation names researchers whose publications have been most cited worldwide 15 researchers from Heidelberg University feature on the recently published list of “Highly Cited Researchers”. This international evaluation names researchers whose publications have been cited most frequently worldwide in their respective field or who have an outstanding track-record of publications across several disciplines. The […]
read more
Biodiversity research and Phylogenetic trees: “Highly Cited Researcher“ at HITS
For nine years running, computer scientist Alexandros Stamatakis from the Heidelberg Institute for Theoretical Studies (HITS) has been identified as one of the most cited researchers worldwide, according to this year’s “Highly Cited Researchers” list from Clarivate. The ranking is an important indicator for the impact of a researcher’s scientific publications. Computer scientist Alexandros Stamatakis from the […]
read more
DKFZ: Twelve scientists ranking in the top 1%
Twelve scientists who conduct research at the German Cancer Research Center (DKFZ) or head joint bridge departments with the DKFZ have made it to the top in 2024: they are among the leading one percent of the world’s most cited researchers in their respective fields. Scientists whose work is particularly frequently cited by peers are […]
read more
VectorBuilder Wins BioIndustrial Innovation of the Year Award
Chicago, IL – NOVEMBER 19, 2024 – VectorBuilder, a global leader in gene delivery solutions, is excited to announce that it’s received the BioIndustrial Innovation of the Year award by the BioTech Breakthrough Awards. The recognition underscores VectorBuilder’s significant contributions to gene delivery technology through its Vector Design Studio, which has revolutionized the way researchers worldwide create and order custom […]
read more
Interdisciplinary Joint Project: New Bioengineering Approaches for the Automated Production of Complex Organoids
The Carl-Zeiss-Stiftung is funding Heidelberg-based research into molecular systems engineering with six million euros The reproducible and precise production of complex organoid models to simulate human organ malfunctions is the focus of an interdisciplinary research project at Heidelberg University. A research team from the life and engineering sciences is looking to combine the engineering of […]
read more
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
NORTH CHICAGO, Ill., Nov. 18, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. ELAHERE […]
read more
